Cargando…
Is CIS a Contraindication to Hyperthermic Intravesical Chemotherapy (HIVEC) after BCG-Failure?
SIMPLE SUMMARY: Intravesical instillations of BCG remain the standard of care for high-risk non-muscle-invasive bladder cancer (NMIBC). In the case of BCG failure, radical cystectomy is recommended. When patients refuse to undergo BCG or are ineligible due to comorbidities, bladder-sparing technique...
Autores principales: | Anastay, Vassili, Baboudjian, Michael, Masson-Lecomte, Alexandra, Lebacle, Cédric, Chamouni, Alexandre, Irani, Jacques, Tillou, Xavier, Waeckel, Thibaut, Monges, Arnaud, Duperron, Céline, Gravis, Gwenaelle, Walz, Jochen, Lechevallier, Eric, Pignot, Géraldine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001134/ https://www.ncbi.nlm.nih.gov/pubmed/36900247 http://dx.doi.org/10.3390/cancers15051455 |
Ejemplares similares
-
Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial
por: Guerrero-Ramos, Félix, et al.
Publicado: (2022) -
A scalable hyperthermic intravesical chemotherapy (HIVEC) setup for rat models of bladder cancer
por: Van Hattum, J. W., et al.
Publicado: (2022) -
Impact of systemic inflammatory markers on the response to Hyperthermic IntraVEsical Chemotherapy (HIVEC) in patients with non-muscle-invasive bladder cancer after bacillus Calmette–Guérin failure
por: Chiancone, Francesco, et al.
Publicado: (2021) -
Hyperthermic Intravesical Chemotherapy for BCG Unresponsive Non-Muscle Invasive Bladder Cancer Patients
por: de Jong, Joep J., et al.
Publicado: (2018) -
Long-Term Experience with Hyperthermic Chemotherapy (HIVEC) Using Mitomycin-C in Patients with Non-Muscle Invasive Bladder Cancer in Spain
por: Plata, Ana, et al.
Publicado: (2021)